Metronidazol Noridem (Metronidazole)

Metronidazole is taken up by susceptible anaerobic bacteria and protozoa, where intracellular reduction converts it to nitro‑radical intermediates. These reactive species bind to DNA, causing strand breakage and inhibition of nucleic acid synthesis, and also disrupt essential proteins, leading to irreversible cell damage and death of the pathogen.

The dosage and duration of Metronidazol Noridem are determined by the prescribing clinician according to the type and severity of the infection, patient age, weight, renal and hepatic function, and any concomitant therapies. The product is supplied as an injectable solution for intravenous administration, and the prescriber sets the exact regimen.

Safety data for metronidazole in pregnancy are limited, and the drug is classified as pregnancy category unknown. It should be used only when clearly needed and after evaluating potential benefits versus risks. Metronidazole is excreted in breast milk; nursing mothers should consult a healthcare professional before continuing therapy.

To request Metronidazol Noridem, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Metronidazole is a nitroimidazole with strong activity against obligate anaerobes and certain protozoa, offering a broad spectrum that many beta‑lactam antibiotics lack. Compared with agents such as clindamycin or carbapenems, metronidazole provides a convenient intravenous option with a well‑characterized safety profile, though resistance patterns and specific infection sites guide the final choice.

Metronidazol Noridem should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Maintaining the cold chain preserves drug stability and potency until administration.

The product is supplied as a sterile injectable solution for intravenous infusion. Healthcare professionals dilute the required volume with an appropriate compatible fluid, then administer it over the prescribed period, typically via a peripheral or central line, following aseptic technique and institutional infusion guidelines.

Serious adverse reactions include severe allergic responses (anaphylaxis), neurologic events such as seizures or peripheral neuropathy, Stevens‑Johnson syndrome or toxic epidermal necrolysis, hepatotoxicity, and hematologic abnormalities like neutropenia. Patients should be monitored for these signs, and therapy should be discontinued if they occur.

Metronidazol Noridem is contraindicated in individuals with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is also advised for patients with severe hepatic or renal impairment, those taking interacting medications such as warfarin, lithium or alcohol, and pregnant or lactating women unless the benefit clearly outweighs the risk.